Abbott Laboratories (ABT)
| Market Cap | 191.09B |
| Revenue (ttm) | 39.96B |
| Net Income (ttm) | 5.16B |
| Shares Out | 1.74B |
| EPS (ttm) | 2.94 |
| PE Ratio | 37.44 |
| Forward PE | 23.90 |
| Dividend | $2.20 (2.00%) |
| Ex-Dividend Date | Jan 11, 2024 |
| Volume | 2,453,999 |
| Open | 110.40 |
| Previous Close | 110.40 |
| Day's Range | 109.83 - 110.73 |
| 52-Week Range | 89.67 - 115.83 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 124.50 (+13.11%) |
| Earnings Date | Jan 24, 2024 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipi... [Read more]
Financial Performance
In 2022, ABT's revenue was $43.65 billion, an increase of 1.34% compared to the previous year's $43.08 billion. Earnings were $6.93 billion, a decrease of -1.95%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price forecast is $124.5, which is an increase of 13.11% from the latest price.
News
Abbott to Present at J.P. Morgan Healthcare Conference
ABBOTT PARK, Ill., Dec. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 42nd annual J.P.
Abbott Increases Quarterly Dividend for 52nd Consecutive Year
Dividend increased by 7.8% 400th consecutive quarterly dividend to be paid by Abbott since 1924 Company continues to deliver strong shareholder returns and top-tier growth ABBOTT PARK, Ill., Dec. 15, ...
Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk o...
Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.
That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.
Abbott India's Q2 profit climbs on strong sales
Abbott India , the local unit of U.S. healthcare firm Abbott Laboratories , reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment.
Participants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes
Study by Public Health Institute shows people with diabetes were able to lower A1C levels, better self-manage diabetes, and improve overall diet and food security at 12 months Abbott's Healthy Food Rx...
Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV
According to the U.S. Centers for Disease Control (CDC), most sexually active adults will experience HPV infections; new test detects those HPV genotypes that could lead to cancer Abbott's new HPV tes...
Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology
Abbott and Shepherd aim to raise awareness of the rising rates of diabetes diagnoses and how access to continuous glucose monitoring (CGM) systems can reduce diabetes-related complications1, provide b...
Abbott and Damar Hamlin Team Up to Build Heart Health Community with New HeartMates Program
HeartMates will create a supportive and empowering community for people impacted by heart conditions, leveraging Abbott's leadership in cardiovascular care Professional football player and heart healt...
Is Abbott Stock Undervalued At $95?
Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates.
FDA issues warning letter to Abbott for probiotic products for infants
The U.S. Food and Drug Administration said on Thursday it has issued a warning letter to Abbott Laboratories for the company's probiotic products sold under the brand Similac Probiotic Tri-Blend for u...
Ninety-One Percent of Young Adults With Student Loans Say Financial Stress is Impacting Their Wellness -- Abbott Launches Blueprint of Award-Winning Program to Help Companies Tackle This Problem
New survey by Morning Consult on behalf of Abbott shows student loans are having a profound and far-reaching impact on young adults and their planning for the future 91% say financial stress is impact...
Late-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care
Abbott's new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time after it's opened a clogged artery There is...
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid...
The Value Deepens for Medtech Stocks: Reversal Imminent
Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength...
Medical device makers see limited hit from weight-loss drugs
U.S. medical device makers do not see a big impact of new weight-loss treatments on the sales of equipment used in procedures such as bariatric surgery due to the prohibitive costs of the drugs as wel...
Abbott Earnings Show Obesity Drug Worries Are Overblown
CEO Robert Ford said more users of its glucose monitoring system were using the device while also taking new obesity drugs.
'We don't see' weight-loss drugs impacting medical devices' sales, says Abbott CEO Robert Ford
Robert Ford, Abbott chairman and CEO, joins 'Closing Bell Overtime' to talk Q3 earnings, the impact of weight loss drugs on their product and more.
Oversold and Overextended, Abbott Laboratories is a Great Buy
Abbott Laboratories NYSE: ABT share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market to sell...
Abbott Stock Is Rising. Earnings Beat and Guidance Was Strong.
Healthcare-products firm Abbott beat third-quarter estimates despite a drop in sales of Covid-19 testing kits. It raised the midpoint of earnings guidance for the year.
Abbott Labs shares rise as company beats earnings estimates, raises full-year guidance
Abbott Laboratories shares ABT, -0.04% climbed 2.5% premarket on Wednesday after the healthcare products company posted a better-than-expected third-quarter profit and raised its earnings guidance for...
Abbott beats profit estimates on strong sales of devices, diagnostics
Abbott Laboratories on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings due to strong demand for its medical devices and diagnostics products.
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
Sales of $10.1 billion driven by strong underlying base business performance Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic...